NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 6.35%.
NPS Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased to $-0.13 in the quarter versus EPS of $0.08 in the year-earlier quarter.
Revenue: Decreased 31.78% to $36.51 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: NPS Pharmaceuticals, Inc. reported adjusted EPS loss of $0.13 per share. By that measure, the company missed the mean analyst estimate of $-0.07. It beat the average revenue estimate of $31.62 million.
Quoting Management: “Having successfully addressed the fill-finish issue, we are pleased to report that we will file our Biologic License Application for Natpara before the end of this year,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “Our commitment to flawless execution has yielded solid second quarter results including Gattex sales that exceeded our own expectations. We are particularly gratified to have already brought this life-changing treatment to 141 Short Bowel Syndrome patients and I am pleased to report that we are increasing our guidance to 275 to 325 patients on therapy by the end of the year.”
Key Stats (on next page)…